The main conclusion was that CBD in the 200-300 mg/day range in adults is usually well tolerated given the short lengths of treatment reported, no information could be obtained regarding the safety of long-term CBD treatment.

Randomized double-blind placebo-controlled trials are required to determine the efficacy of CBD, CBD-THC combinations, or other cannabis products as potential treatments for epilepsy.

Although many marijuana strains used for epilepsy treatment are reported to have high CBD:THC ratios, THC is more potent than CBD, so low doses of THC can have adverse effects, especially in young children.

Pure CBD appears to be an excellent candidate among phytocannabinoids to evaluate in patients with treatment-resistant epilepsy.

A reasonable development program for CBD in the treatment of epilepsy will obtain initial observations from a dose-tolerability and pharmacokinetic study.

We believe a critical first step is systematical investigation of CBD, or other well-defined compounds or products as potential epilepsy therapies.

Characterizing the safety and efficacy of marijuana products and their possible role in treating epilepsy in children and adults depends on gathering rigorous clinical experience and data from randomized placebo-controlled, double blind studies-whether of medicinal marijuana or single compounds such as CBD..

Cilio The case for assessing cannabidiol in epilepsy Epilepsia 2014